Compare Cemex S.A.B. de C.V. Sponsored ADR (CX) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cemex S.A.B. de C.V. Sponsored ADR vs Mesoblast Limited — how do they compare? Cemex S.A.B. de C.V. Sponsored ADR trades at $9.46 (market cap $13.79B), while Mesoblast Limited trades at $14.3 (market cap $1.75B). The key difference: Cemex S.A.B. de C.V. Sponsored ADR is far larger — about 7.9× Mesoblast Limited's market cap, and Cemex S.A.B. de C.V. Sponsored ADR pays a 1.3% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cemex S.A.B. de C.V. Sponsored ADR for 0 Days and Mesoblast Limited for 15 Days on average.
| CX | MESO | |
|---|---|---|
Market Cap | $13.79B | $1.75B |
Volume | 3,993,982 | 239,027 |
Sector | Basic Materials | Health |
52-Week High | $13.55 | $20.96 |
52-Week Low | $9.12 | $13.19 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $19.79B | $1.83B |
Dividend Yield | 1.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cemex S.A.B. de C.V. Sponsored ADR
Cemex produces, distributes, markets, and sells cement, ready-mix concrete, aggregates, and other construction materials. Its operations serve markets around the world.
Read more on CX →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
